BRCA Mutation Testing in Men with Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice
- Author(s)
- Azad, AA; Gurney, H; Campbell, A; Goh, JC; Rathi, V;
- Journal Title
- Asia-Pacific Journal of Clinical Oncology
- Publication Type
- Online publication before print
- Abstract
- Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC. There are practical challenges in the current molecular testing pathway in Australia that can compromise testing success. Testing success is often contingent on quality of tissue handling and laboratory processing techniques to minimize DNA degradation and suboptimal sequencing data quality. Greater adoption of best testing practices in Australia can be facilitated with education and greater awareness of expert recommendations. Here, we provide expert recommendations on how to optimize BRCA molecular diagnostic testing in patients with mCRPC. Optimization and standardization of molecular diagnostic testing will support health care providers and institutes in establishing more efficient testing pathways, enabling access to targeted therapies such as PARPi, and improving patient outcomes.
- Keywords
- Brca1; Brca2; genetic testing; mCRPC; poly(adenosine diphosphate [ADP]‐ribose polymerase inhibitors; prostate cancer
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1111/ajco.14150
- Open Access at Publisher's Site
https://doi.org/10.1111/ajco.14150- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-28 02:47:03
Last Modified: 2025-01-28 02:54:38